
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy

Gabrielle Leclercq, Hélène Haegel, Alberto Toso, Tina Zimmermann, Luke Green, Nathalie Steinhoff, Johannes Sam, Vesna Pulko, Anneliese Schneider, Anna-Maria Giusti, John Challier, Anne Freimoser-Grundschober, Laurent Larivière, Alex Odermatt, Martin Stern, Pablo Umaña, Marina Bacac, Christian Klein



Key points

• Targeting JAK, mTOR and Src pathways reveals the uncoupling of TCB-induced T cell cytotoxicity and cytokine release.

• mTOR and JAK inhibitors prevent TCB-mediated cytokine release upon first infusion while preserving TCB-efficacy.

correspondance

gabrielle.leclercq@roche.com